Home > Inhibitors & Agonists > Others > Other Targets

Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC21250 Lopixibat chloride Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT)..
DC1011 Lorcaserin Featured Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
DC8644 Lorcaserin Hydrochloride Featured Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
DC8645 Lorcaserin hydrochloride heMihydrate Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
DC10254 L-Ornithine L-ornithine has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.
DC8356 Losartan Carboxylic Acid Featured Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.
DC2105 Lovastatin (MK-803) Featured Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).
DC8066 Loxiglumide Featured Loxiglumide is a Exogenous cholecystokinin (CCK-A) receptor antagonist, stimulates calorie intake and hunger feelings in humans.
DC22338 Larotrectinib (LOXO-101 free base) Featured LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.
DC10867 LP-211 Featured LP-211 is a selective and blood−brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM).
DC23403 LP99 Featured LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.
DC20000 LR-90 Featured LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model.
DC20086 LRE1 Featured LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.
DC12514 LSD1 inhibitor 24 LSD1 inhibitor 24 is a novel potent, selective lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 1 nM, induces CD11b expression in THP-1 cells with EC50 of 8 nM.
DC22396 LSD1 inhibitor-1 LSD1 inhibitor-1 is a bisguanidine polyamine analogue that exhibits noncompetitive and specific LSD1 inhibition, with 14.1% remaining LSD1 activity at 10 uM in vitro.
DC23384 LSD1-IN-11p LSD1-IN-11p is a reversible LSD1 inhibitor with IC50/Kd of 79/21 nM.
DC23379 LSD1-IN-32 LSD1-IN-32 is a potent, reversible lysine specific demethylase 1 (LSD1) inhibitor with biochemical IC50 of 83 nM, Kd of 32 nM, cell EC50 of 0.67 uM.
DC8698 L-SelenoMethionine L-SelenoMethionine is a major natural food-form of selenium.
DC21249 LSN 3213128 Featured LSN 3213128 is a novel potent, selective and orally-bioavailable antifolate with potent and specific inhibitory activity for AICARFT.
DC7878 LSN2814617 Featured LSN2814617 is a neurotoxic positive allosteric modulator.
DC23503 LSP1-2111 LSP1-2111 is a potent, selective, and brain penetrant group III mGluRs agonist with EC50 of 2.2 and 1.7 uM for mGluR4 and mGluR6, respectively.
DC26113 LSP4–2022 Featured LSP4–2022 is a novel potent, selective, brain-penetrant mGluR4 agonist with EC50 of 0.11 uM in cell-based assays.
DCAPI1211 L-Thyroxine L-Thyroxine
DC10072 LTI-291 Featured LTI-291 is a Glucocerebrosidase (Gcase) activator for the treament of Parkinson's disease (PD).
DC10155 LTURM34 LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM.
DC24031 LTV-1 LTV-1 is a highly potent, cell-permeable and reversible LYP (lymphoid tyrosine phosphatase) inhibitor with IC50 of 508 nM.
DC10987 LTX-315 This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis.
DC10988 LTX-401 Featured LTX-401 is a novel oncolytic amino acid derivative that specifically targets the Golgi apparatus, demonstrating significant potential in cancer therapy. In vitro studies reveal that LTX-401 effectively reduces the viability of various tumor cell lines, exhibiting cytotoxic activity across a range of concentrations. Notably, it shows the highest potency against the human malignant melanoma cell line MDA-MB-435S (IC50 = 13.5 μM) and the lowest activity against the human hepatocellular carcinoma cell line HEPG2 (IC50 = 35.4 μM). For other cell lines, the IC50 values fall within a narrow range of 19-32 μM. Importantly, LTX-401 does not induce hemolysis in red blood cells at concentrations effective for cancer cell death, with hemolytic activity only observed at much higher concentrations (400 μg/mL = 1087 μM). Additionally, LTX-401 demonstrates cytotoxicity against non-malignant cell lines, including HUV-EC-C endothelial cells, HaCat keratinocytes, and MRC-5 fibroblasts, suggesting a broad but selective mechanism of action.
DC9784 Lu AF21934 Featured Lu AF21934 is a brain-penetrating positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4),reduces the harmaline-induced hyperactivity
DC8287 Lubiprostone Featured Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X